Strong Genetic

Sickle Cell Disease / Beta-Thalassemia (combined HBB entry)

GeneHBBrsIDrs334, rs11549407, rs33930165, rs35004220, rs11549407, rs33950507InheritanceAutosomal recessive (including compound heterozygosity across variants)Carrier frequencySickle cell trait: ~1 in 12 African Americans, ~1 in 4 West Africans, elevated in Mediterranean, Middle Eastern, South Asian. Beta-thalassemia trait: ~1 in 7 Sardinians, ~1 in 7 Cypriots, common across Mediterranean, South and Southeast Asian populations.SystemCarrier Screening

Summary

Sickle cell disease and beta-thalassemia are both disorders of haemoglobin — the protein in red blood cells that carries oxygen. They are caused by different variants in the same gene (HBB) and are grouped here because of that shared genetic basis.

Practical takeaway

This is where carrier status for HBB variants becomes critically important — and where compound heterozygosity makes this entry more complex than most carrier conditions.

Key combinations that produce disease in offspring:
• HbS + HbS = sickle cell disease (SS)
• HbS + beta-thal variant = sickle-beta thalassemia (a form of sickle cell disease)
• HbS + HbC = haemoglobin SC disease (milder but still clinically significant)
• Beta-thal + beta-thal = beta-thalassemia major or intermedia

This means a sickle cell carrier whose partner is a beta-thalassemia carrier still faces a 25% chance per pregnancy of a child with sickle-beta thalassemia. The conditions don't have to match — any two pathogenic HBB variants can combine.

Partner testing is a blood test — specifically a haemoglobin electrophoresis or HPLC, which identifies the haemoglobin types present. This is more informative than genotyping alone for HBB because it directly measures protein output. A genetic counsellor can integrate both partners' results and ancestry to provide accurate risk assessment.

Evidence detail

What Carrier Status Means For You

Sickle cell trait (one HbS copy): You are generally healthy, but sickle cell trait is not entirely silent. There are specific situations where it has mild clinical relevance:
• Extreme exertion: Increased risk of exertional rhabdomyolysis and exercise-related sudden death, particularly at altitude or in extreme heat. This is rare but documented — the military and NCAA both have screening protocols.
• High altitude: Splenic infarction risk above ~2,500m / 8,000ft, especially with rapid ascent and vigorous activity.
• Renal effects: Slightly increased risk of renal papillary necrosis and haematuria over a lifetime.
• Anaesthesia: Worth mentioning to your anaesthetist for procedures, as extreme deoxygenation should be avoided.

None of these mean you have sickle cell disease. They mean your body has one context-specific vulnerability worth knowing about.

Beta-thalassemia trait (one beta-thal copy): You likely have mildly small red blood cells (low MCV) and possibly mild anaemia that doesn't respond to iron supplementation. This is often picked up incidentally on a routine blood count. It has no significant health impact but is frequently mistaken for iron deficiency — if you've been prescribed iron for persistent mild anaemia without confirmed iron deficiency, thalassemia trait is worth investigating.

Population Context

The geographic distribution of HBB variants maps directly onto historical malaria exposure. Carriers of sickle cell trait and beta-thalassemia trait have a survival advantage against Plasmodium falciparum malaria — one of the strongest known examples of heterozygote advantage in human genetics.

This is why sickle cell trait is most common in sub-Saharan Africa, the Middle East, and parts of South Asia where malaria was historically endemic. Beta-thalassemia follows a similar but distinct pattern across the Mediterranean, Middle East, and South/Southeast Asia — regions often called the "thalassemia belt."

In populations with mixed or recent immigrant ancestry, carrier status can be unpredictable from appearance or self-reported ethnicity alone. Universal newborn screening for sickle cell disease is standard in most high-income countries precisely because ancestry-based screening misses cases.

Limitations

Consumer genotyping chips have significant limitations for HBB variants:

Sickle cell: 23andMe tests only rs334 (HbS). This single variant is highly reliable for detecting sickle cell trait — if you carry it, you carry it. But it misses other rare haemoglobin variants (HbD, HbE, HbO-Arab) that can also combine with HbS to produce disease.

Beta-thalassemia: 23andMe tests approximately 10 of the more than 300 known beta-thalassemia variants. Coverage is reasonable for Mediterranean-origin variants but drops substantially for South Asian and Southeast Asian populations where different variants predominate. A negative result on a consumer chip provides much less reassurance for beta-thalassemia than for sickle cell.

Compound heterozygosity: Consumer reports may not explicitly flag that carrying one sickle variant AND one beta-thal variant in the same person means their children's risk profile differs from carrying two copies of the same variant. This is a nuance that requires genetic counselling.

A "not detected" result does NOT mean zero carrier risk, particularly for beta-thalassemia. Haemoglobin electrophoresis (a standard clinical blood test) is the gold-standard carrier screen for HBB-related conditions and catches what genotyping misses.

Sources (7)

Open in the Library: search, filter, every entry →